Your browser doesn't support javascript.
loading
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.
Dimitriou, F; Namikawa, K; Reijers, I L M; Buchbinder, E I; Soon, J A; Zaremba, A; Teterycz, P; Mooradian, M J; Armstrong, E; Nakamura, Y; Vitale, M G; Tran, L E; Bai, X; Allayous, C; Provent-Roy, S; Indini, A; Bhave, P; Farid, M; Kähler, K C; Mehmi, I; Atkinson, V; Klein, O; Stonesifer, C J; Zaman, F; Haydon, A; Carvajal, R D; Hamid, O; Dummer, R; Hauschild, A; Carlino, M S; Mandala, M; Robert, C; Lebbe, C; Guo, J; Johnson, D B; Ascierto, P A; Shoushtari, A N; Sullivan, R J; Cybulska-Stopa, B; Rutkowski, P; Zimmer, L; Sandhu, S; Blank, C U; Lo, S N; Menzies, A M; Long, G V.
Afiliación
  • Dimitriou F; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Department of Dermatology, University Hospital Zurich (USZ) and University of Zurich (UZH), Zurich, Switzerland; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
  • Namikawa K; Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Reijers ILM; Department of Medical Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Buchbinder EI; Melanoma Disease Center, Dana-Farber Cancer Institute, Boston, USA.
  • Soon JA; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Zaremba A; Department of Dermatology, University Hospital Essen, Essen, Germany.
  • Teterycz P; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Mooradian MJ; Division of Oncology and Hematology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
  • Armstrong E; Department of Medicine, Melanoma Service, Memorial Sloan Kettering Cancer Center, New York, USA.
  • Nakamura Y; Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, Japan.
  • Vitale MG; Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Napoli, Italy.
  • Tran LE; Department of Medicine, Vanderbilt University Medical Center, Nashville, USA.
  • Bai X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Beijing, China.
  • Allayous C; APHP Hôpital Saint-Louis, Dermatology Department, DMU ICARE, Paris, France.
  • Provent-Roy S; Dermatology Service, Department of Medicine, Gustave Roussy and Paris-Saclay University, Villejuif, France.
  • Indini A; Unit of Medical Oncology, Ospedale di Circolo e Fondazione Macchi, ASST Sette Laghi, Varese, Italy.
  • Bhave P; Westmead and Blacktown Hospitals, Sydney, Australia.
  • Farid M; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
  • Kähler KC; Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Germany.
  • Mehmi I; Department of Hematology/Oncology, The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, USA.
  • Atkinson V; Princess Alexandra Hospital, Greenslopes Private Hospital, University of Queensland, Queensland, Australia.
  • Klein O; Department of Medical Oncology, Austin Health, Melbourne, Australia; Olivia Newton-John Cancer Research Institute, Melbourne, Australia.
  • Stonesifer CJ; Columbia University Irving Medical Center, New York City, USA.
  • Zaman F; Alfred Hospital, Melbourne, Australia.
  • Haydon A; Alfred Hospital, Melbourne, Australia.
  • Carvajal RD; Columbia University Irving Medical Center, New York City, USA.
  • Hamid O; Department of Hematology/Oncology, The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, USA.
  • Dummer R; Department of Dermatology, University Hospital Zurich (USZ) and University of Zurich (UZH), Zurich, Switzerland.
  • Hauschild A; Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Germany.
  • Carlino MS; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Westmead and Blacktown Hospitals, Sydney, Australia.
  • Mandala M; Unit of Medical Oncology, University of Perugia, Perugia, Italy.
  • Robert C; Dermatology Service, Department of Medicine, Gustave Roussy and Paris-Saclay University, Villejuif, France.
  • Lebbe C; Université de Paris, APHP Hôpital Saint-Louis, Dermatology Department, DMU ICARE, INSERM U-976, Paris, France.
  • Guo J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Beijing, China.
  • Johnson DB; Department of Medicine, Vanderbilt University Medical Center, Nashville, USA.
  • Ascierto PA; Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Napoli, Italy.
  • Shoushtari AN; Department of Medicine, Melanoma Service, Memorial Sloan Kettering Cancer Center, New York, USA.
  • Sullivan RJ; Division of Oncology and Hematology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
  • Cybulska-Stopa B; Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow, Poland.
  • Rutkowski P; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Zimmer L; Department of Dermatology, University Hospital Essen, Essen, Germany.
  • Sandhu S; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Blank CU; Department of Medical Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Lo SN; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
  • Menzies AM; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia.
  • Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia. Electronic address: Georgina.long@sydney.edu.au.
Ann Oncol ; 33(9): 968-980, 2022 09.
Article en En | MEDLINE | ID: mdl-35716907
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Pulmonares / Melanoma Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Pulmonares / Melanoma Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article